On October 23, 2025, Qingdao Baheal Medical INC. (Stock Code: 301015.SZ) signed a strategic cooperation agreement with Peking University International Hospital to jointly establish a Precise Radiotherapy Center. This center is set to be established at Peking University International Hospital, and will be equipped with ZAP-X® Gyroscopic Radiosurgery™ Platform, the core product of ZAP Surgical, which is the portfolio company of Baheal Medical. This cooperation will focus on disease-specific treatment for brain tumors, offering millions of patients innovative precision radiotherapy solutions.

Signing Ceremony

Brain tumors present a global therapeutic challenge. Even successful surgical resection can result in neurological damage or secondary complications such as cerebral edema. Most drugs are unable to cross the blood-brain barrier effectively, limiting therapeutic outcomes. Incidence of brain tumors has been rising, particularly for brain metastases. In 2022, approximately 20 million new cancer cases were reported worldwide, with 20%-40% of malignancies potentially developing brain metastases. In China, the annual incidence of brain metastases exceeds 1.5 million per year.

The jointly-established radiotherapy center will feature ZAP-X system—honored as a revolutionary advancement in intracranial radiosurgery. This platform significantly enhances the precision and safety of brain tumor treatments through its globally pioneering dual-gantry spherical structure, which delivers X-rays from thousands of non-coplanar angles. This design enables highly efficient tumor ablation while effectively preserving surrounding healthy brain tissue. Further reinforcing treatment accuracy and safety, the system incorporates sub-millimeter isocentric precision and real-time dose imaging with dual monitoring. Backed by its demonstrated advantages in precision brain tumor radiotherapy, ZAP-X has obtained market approval in 24 countries and regions worldwide and has successfully completed over 5,000 clinical treatments.

At the ceremony, Zhu Yougang, Secretary of the Party Committee and Chairman of PKU HealthCare Industry Group Co.,Ltd, stated that this strategic cooperation not only marks a new starting point for both parties, but also represents a forward-looking practice in healthcare service innovation and industrial exploration. As the flagship of Ping An Group's offline future development, Peking University International Hospital remains a key focus of the Group's strategic investments. He expressed hope that through this collaboration, both sides will jointly develop leading domestic diagnostic and treatment capabilities in oncology, particularly in brain tumor treatment. Furthermore, he looked forward to using this opportunity to initiate new cooperation in more critical areas, working together to build a healthcare model characterized by technological leadership, service excellence, and superior patient experience, thereby advancing medical and health progress through mutual development.

Zhu Yougang, Secretary of the Party Committee and Chairman of PKU HealthCare Industry Group Delivered Speech

Fu Gang, Chairman of Baheal Pharma Group, stated that the collaboration with Peking University International Hospital represents a significant step in advancing the clinical implementation of high-end radiotherapy equipment and improving the accessibility of high-quality medical resources. It also serves as a concrete practice of Baheal's commitment to optimizing healthcare scenarios through technological innovation. Having established a comprehensive industrial chain in radiotherapy spanning from R&D and production to operations, Baheal will continue to promote the construction of precision radiotherapy centers and introduce more advanced radiotherapy devices into clinical practice, ensuring that technological innovation tangibly benefits more Chinese patients.

Fu Gang, Chairman of Baheal Pharma Group Delivered Speech

Liang Jun, Party Secretary and Executive President of Peking University International Hospital, noted that the hospital has a deep foundation in oncology care. It hosts the Clinical Education Base of the Pain Management Academy of the Chinese Anti-Cancer Association and the Demonstration Base for Standardized Diagnosis and Treatment of Refractory Pain of the China Oncology Hospital Alliance. In partnership with leading domestic and international cancer centers and national key laboratories, the hospital has developed platforms for precision molecular testing, integrated immunotherapy, complex case consultations, multidisciplinary tumor treatment, novel drug R&D and translation, and minimally invasive therapies. The introduction of ZAP-X extends the hospital’s precision treatment philosophy, offering patients a fully integrated approach of personalized radiotherapy + systemic therapy + full-cycle management.

Liang Jun, Party Secretary and Executive President of Peking University International Hospital Delivered Speech
 

In recent years, Baheal Medical has accelerated its transformation into a technology-driven enterprise. Its precision radiotherapy ecosystem now spans brain, body, and cardiac treatment, supported by a global marketing network for large medical equipment.

In the field of brain tumor radiosurgery, through a strategic investment in 2024, Baheal Medical introduced ZAP to accelerate its clinical deployment and global manufacturing in China, and will promote the clinical application of equipment through the establishment of precise radiotherapy centers. In February 2025, ZAP-X officially joined the China Intracranial Metastases Collaborative Group, actively participating in the establishment of standardized brain metastasis care. Baheal’s high-end manufacturing base in Beijing Airport Economic Zone is slated to open by the end of 2025, serving as the global production and supply center for ZAP-X, achieving “Made in China, delivered globally.”

Wang Tingwei, Vice President of Baheal Medical Introduced ZAP-X

In the field of body radiotherapy, Huake Pioneer, an innovative enterprise incubated by Baheal Pharma Group, has independently developed China's first 4π intelligent robotic radiotherapy system. Its globally pioneering Q-arm enables comprehensive 4π spherical radiation delivery, significantly enhancing treatment flexibility and precision. The system has currently entered the clinical trial phase. In the pioneering area of cardiac radiotherapy, Baheal has strategically applied stereotactic radiotherapy technology to arrhythmia treatment, potentially establishing a completely new paradigm for non-invasive arrhythmia management.

This comprehensive radiotherapy ecosystem not only demonstrates Baheal’s innovation leadership in radiotherapy equipment but also positions the company as a key player in global precision radiotherapy. This collaboration represents a deep integration of Peking University International Hospital’s clinical expertise and Baheal Medical’s industrial innovation experience, jointly advancing the nation’s brain tumor treatment capabilities and setting a new benchmark for high-quality healthcare development in China.

Liu Yajuan, General Manager of PKU HealthCare Industry Group Delivered the Concluding Remarks